Health TrialsbyHealthPanel

Angiotensin Receptor Blockers in Aortic Stenosis

ConditionsAortic StenosisAortic Valve Stenosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age20-99
SponsorInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval

About this trial

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)

Normal left ventricular ejection fraction (i.e. ≥50%)

Systolic blood pressure >110 mmHg

Diastolic blood pressure >70 mmHg

Disqualifiers

More than mild aortic or mitral regurgitation, or mitral stenosis

Current use or documented indication for renin-angiotensin system medication or Aliskiren

Known allergy or intolerance to angiotensin II receptor blockers (ARBs)

Alzheimer, dementia or known non-compliant patient

Trial design

Design model

Parallel

Treatments tested in this trial

  • Angiotensin Receptor Blockers

    Drug

    Angiotensin Receptor Blockers treatment for 2 years.

  • Placebo

    Other intervention

    Placebo administration for 2 years.

Treatment groups

144 Participants
are divided into 2 treatment groups
Group A: Angiotensin Receptor BlockersExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in the anatomic progression of aortic stenosis

Aortic valve calcification (measured by MDCT)

Time frame
Baseline, 2 years

Secondary outcomes

1

Change in peak aortic jet velocity

peak aortic jet velocity (Echocardiography)

Time frame
Baseline, 2 years
2

Change in aortic valve area

Aortic valve area (Echocardiography)

Time frame
Baseline, 2 years
3

Change in left ventricular (LV) dimension

LV dimension (Echocardiography, MRI)

Time frame
Baseline, 2 years
4

Change in left ventricular (LV) mass

LV mass (Echocardiography, MRI)

Time frame
Baseline, 2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Lead sponsor

Odense University Hospital

Collaborator

Source ClinicalTrials.gov
Apply now